Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28584
Title: Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study.
Austin Authors: Bischof, Gérard N;Bartenstein, Peter;Barthel, Henryk;van Berckel, Bart;Doré, Vincent ;van Eimeren, Thilo;Foster, Norman;Hammes, Jochen;Lammertsma, Adriaan A;Minoshima, Satoshi;Rowe, Chris;Sabri, Osama;Seibyl, John;Van Laere, Koen;Vandenberghe, Rik;Villemagne, Victor L ;Yakushev, Igor;Drzezga, Alexander
Affiliation: Molecular Imaging and Therapy
University Hospital Cologne, Multimodal Neuroimaging Group, Department of Nuclear Medicine, Cologne, Germany
CSIRO Health and Biosecurity, Parkville 3052, Victoria, Australia
Department of Neurology, University Hospital Cologne, Cologne, Germany
German Center of Neurodegenerative Disease (DZNE), Bonn, Germany
Department of Nuclear Medicine, LMU Munich, Munich, Germany
University Hospital of Leipzig, Department of Nuclear Medicine, Leipzig, Germany
Amsterdam University Medical Centers, Location VUmc Radiology and Nuclear Medicine, Amsterdam, The Netherlands
Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, Utah
Institute for Neurodegenerative Disorders, New Haven, Connecticut
Nuclear Medicine and Molecular Imaging, University Hospital Leuven and Department of Imaging and Pathology KU Leuven, Leuven, Belgium
Memory Clinic, University Hospital Leuven and Department of Neurosciences, KU Leuven, Belgium
Department of Nuclear Medicine, Technical University of Munich, Germany
Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany
Issue Date: 1-Jul-2021
Date: 2021-03-12
Publication information: Journal of Nuclear Medicine 2021; 62(7): 999-1005
Abstract: To date, 3 18F-labeled PET tracers have been approved for assessing cerebral amyloid plaque pathology in the diagnostic workup of suspected Alzheimer disease (AD). Although scanning protocols are relatively similar across tracers, U.S. Food and Drug Administration- and the European Medicines Agency-approved visual rating protocols differ among the 3 tracers. This proof-of-concept study assessed the comparability of the 3 approved visual rating protocols to classify a scan as amyloid-positive or -negative, when applied by groups of experts and nonexperts to all 3 amyloid tracers. Methods: In an international multicenter approach, both expert (n = 4) and nonexpert raters (n = 3) rated scans acquired with 18F-florbetaben, 18F-florbetapir and 18F-flutemetamol. Scans obtained with each tracer were presented for reading according to all 3 approved visual rating protocols. In a randomized order, every single scan was rated by each reader according to all 3 protocols. Raters were blinded for the amyloid tracer used and asked to rate each scan as positive or negative, giving a confidence judgment after each response. Percentage of visual reader agreement, interrater reliability, and agreement of each visual read with binary quantitative measures (fixed SUV ratio threshold for positive or negative scans) were computed. These metrics were analyzed separately for expert and nonexpert groups. Results: No significant differences in using the different approved visual rating protocols were observed across the different metrics of agreement in the group of experts. Nominal differences suggested that the 18F-florbetaben visual rating protocol achieved the highest interrater reliability and accuracy especially under low confidence conditions. For the group of nonexpert raters, significant differences between the different visual rating protocols were observed with overall moderate-to-fair accuracy and with the highest reliability for the 18F-florbetapir visual rating protocol. Conclusion: We observed high interrater agreement despite applying different visual rating protocols for all 18F-labeled amyloid tracers. This implies that the results of the visual interpretation of amyloid imaging can be well standardized and do not depend on the rating protocol in experts. Consequently, the creation of a universal visual assessment protocol for all amyloid imaging tracers appears feasible, which could benefit especially the less-experienced readers.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28584
DOI: 10.2967/jnumed.120.250290
ORCID: 0000-0002-8051-0558
0000-0003-3910-2453
0000-0002-5832-9875
Journal: Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
PubMed URL: 33712532
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/33712532/
Type: Journal Article
Subjects: amyloid PET
florbetaben
florbetapir
flutemetamol
visual rating standardization
Appears in Collections:Journal articles

Show full item record

Page view(s)

24
checked on Apr 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.